Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Francis J. Giles(The University of Texas MD Anderson Cancer Center), Norbert Gattermann(Düsseldorf University Hospital), Kapil N. Bhalla(Moffitt Cancer Center), Giuliana Alimena(Policlinico Umberto I), Francesca Palandri(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Gert J. Ossenkoppele(Vrije Universiteit Amsterdam), Franck-Emmanuel Nicolini(Hôpital Edouard Herriot), Stephen G. O’Brien(Royal Victoria Infirmary), Mark R. Litzow(Mayo Clinic), Ravi Bhatia(City Of Hope National Medical Center), Francisco Cervantes(Hospital Clínic de Barcelona), Md Ariful Haque(Novartis (United States)), Yaping Shou(Novartis (United States)), Debra Resta(Novartis (United States)), Aaron Weitzman(Novartis (United States)), Andreas Hochhaus(Heidelberg University), Philipp le Coutre(Humboldt-Universität zu Berlin)
Blood
August 23, 2007
Cited by 745Open Access
Full Text

Abstract

Nilotinib, an orally bioavailable, selective Bcr-Abl tyrosine kinase inhibitor, is 30-fold more potent than imatinib in pre-clinical models, and overcomes most imatinib resistant BCR-ABL mutations. In this phase 2 open-label study, 400 mg nilotinib was administered orally twice daily to 280 patients with Philadelphia chromosome-positive (Ph(+)) chronic myeloid leukemia in chronic phase (CML-CP) after imatinib failure or intolerance. Patients had at least 6 months of follow-up and were evaluated for hematologic and cytogenetic responses, as well as for safety and overall survival. At 6 months, the rate of major cytogenetic response (Ph < or = 35%) was 48%: complete (Ph = 0%) in 31%, and partial (Ph = 1%-35%) in 16%. The estimated survival at 12 months was 95%. Nilotinib was effective in patients harboring BCR-ABL mutations associated with imatinib resistance (except T315I), and also in patients with a resistance mechanism independent of BCR-ABL mutations. Adverse events were mostly mild to moderate, and there was minimal cross-intolerance with imatinib. Grades 3 to 4 neutropenia and thrombocytopenia were observed in 29% of patients; pleural or pericardial effusions were observed in 1% (none were severe). In summary, nilotinib is highly active and safe in patients with CML-CP after imatinib failure or intolerance. This clinical trial is registered at http://clinicaltrials.gov as ID no. NCT00109707.


Related Papers

No related papers found

Powered by citation graph analysis